Bio-Techne Corp (TECH) To Go Ex-Dividend on August 17th

Bio-Techne Corp (NASDAQ:TECHGet Free Report) declared a quarterly dividend on Wednesday, August 12th. Stockholders of record on Monday, August 17th will be paid a dividend of 0.08 per share by the biotechnology company on Friday, August 28th. This represents a c) dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, August 17th.

Bio-Techne has a dividend payout ratio of 15.4% indicating that its dividend is sufficiently covered by earnings. Analysts expect Bio-Techne to earn $2.01 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 15.9%.

Bio-Techne Trading Up 0.3%

Bio-Techne stock opened at $72.40 on Friday. The stock has a 50-day moving average price of $67.40 and a 200 day moving average price of $59.31. The company has a market capitalization of $11.34 billion, a price-to-earnings ratio of 62.96, a price-to-earnings-growth ratio of 8.60 and a beta of 1.28. Bio-Techne has a 52 week low of $43.19 and a 52 week high of $72.43. The company has a quick ratio of 3.18, a current ratio of 4.55 and a debt-to-equity ratio of 0.09.

Bio-Techne (NASDAQ:TECHGet Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share for the quarter, hitting the consensus estimate of $0.52. Bio-Techne had a net margin of 14.97% and a return on equity of 13.23%. The company had revenue of $321.19 million for the quarter, compared to the consensus estimate of $314.63 million. During the same quarter in the prior year, the company earned $0.53 EPS. Bio-Techne’s quarterly revenue was up 1.3% on a year-over-year basis. Sell-side analysts anticipate that Bio-Techne will post 1.76 EPS for the current year.

About Bio-Techne

(Get Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Featured Articles

Dividend History for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.